• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies reports third quarter and first nine months of 2021 sales

Mauna Kea Technologies reports third quarter and first nine months of 2021 sales

by Zina | Oct 28, 2021 | News

Mauna Kea Technologie announced third quarter and first nine months of 2021 sales results for the periods ended September 30, 2021.  First Nine Months of 2021 Sales Summary:  Total sales for the first nine months of 2021 increased €0.9 million, or...
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the ERS International Congress 2021

Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the ERS International Congress 2021

by Zina | Oct 4, 2021 | News

Further validation of how Cellvizio is a complementary technology to manual and robotic-assisted bronchoscopy, potentially impacting patient management and improving outcomes in multiple pulmonology indications  Mauna Kea Technologies today announces that 5...
Mauna Kea Technologies reports third quarter and first nine months of 2021 sales

Mauna Kea Technologies reports first half 2021 financial results

by Zina | Sep 23, 2021 | News

Mauna Kea Technologies today announced first half 2021 financial results for the six months ended June 30, 2021. First Half 2021 Financial Summary: Total revenue* for the first half of 2021 increased €0.7 million, or 22% year-over-year, to €3.9...
Johnson & Johnson, Mauna Kea launch study of lung cancer biopsy guidance tool

Johnson & Johnson, Mauna Kea launch study of lung cancer biopsy guidance tool

by Zina | Sep 20, 2021 | Press Coverage

No longer will surgeons be flying blind while performing biopsies of peripheral lung nodules—at least, not if Mauna Kea Technologies and Johnson & Johnson’s Lung Cancer Initiative have anything to say about it.   Read the complete...
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the ERS International Congress 2021

Mauna Kea Technologies Announces New Clinical Study and Research Collaboration Agreement with the Lung Cancer Initiative at Johnson & Johnson

by Zina | Sep 20, 2021 | News

Mauna Kea Technologies (the “Company”), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (“pCLE” and “nCLE”) platform, today announced that it has entered into a new...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}